The Longevity Investor Network (LIN) connects innovative startups working on ageing research with investors who can help these companies grow. Through monthly pitches, educational sessions and networking events, investors gain insight into the latest developments surrounding cellular ageing and rejuvenation. This network helps to turn promising research results into tangible companies and products.
Since its establishment in 2020, LIN has supported more than 23 companies worldwide with over 6.7 million dollars in investments. In 2025 alone, more than 1.2 million dollars went to companies working on, for example, cell rejuvenation, regenerative medicine, brain ageing and new diagnostic methods. These are important areas for better tackling or even slowing down age-related disorders.
A striking trend is that many companies are focusing on specific diseases that are more common in older people, such as neurodegeneration. This approach makes treatments more concrete and increases the likelihood of drug approval. At the same time, developments in areas such as brain technology and regenerative therapies demonstrate that extending lifespan is not only a medical challenge, but also offers new business opportunities.
In addition, LIN not only offers investment opportunities, but the network also organises educational meetings and personal encounters. These activities are particularly valuable now that finding money for biotechnological innovations is becoming increasingly difficult. The network thereby contributes to building trust and cooperation between scientists, entrepreneurs and investors.
For everyone who wants to age healthily, it is good news that increasing investments are being made in technologies that tackle ageing processes at the source. This could eventually contribute to better health and more years of quality life.
Source: Editorial
